Parabilis Medicines
Business Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
30 Acorn Park Dr, Cambridge, Massachuset...Phone Number
(617) 945-9510Website
www.parabilismed.comRevenue
-Industry
ZI Rank: 2
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
3
3
1
1
1
2
About Parabilis Medicines
Parabilis Medicines is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines that unlock high-impact protein targets long-considered undruggable. Leveraging over a decade of proprietary data, laboratory innovations, and AI- and physics-based algorithms, the company has developed a new class of stabilized, cell-penetrant alpha-helical peptides Helicons capable of modulating intracellular proteins that are inaccessible to traditional drug modalities.Explore more
Parabilis Medicines Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Parabilis Medicines your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Parabilis Medicines is spiking on competitors!
Parabilis Medicines, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Parabilis Medicines
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Parabilis Medicines launches new products
Funding: Get notified immidiatlly once Parabilis Medicines has new funding data
Click to see if Parabilis Medicines had a recent Job posting/layoffs
Earning: See what the market has to say on Parabilis Medicines recently announced quarterly report
Check if Parabilis Medicines has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Parabilis Medicines is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Parabilis Medicines is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Parabilis Medicines.
Parabilis Medicines financials insights
Gather financial insights about Parabilis Medicines, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Multiple Rounds
$1.1B
Parabilis Medicines Tech Stack
A closer look at the technologies used by Parabilis Medicines
Most Recent Scoops
Person-Based
Strategic Communications, Public Health, Communications
Project
, according to a front-line source in artificial intelligence, is in the midst of initiatives related to conversational intelligence. These efforts are focused on reducing time to development.
Business Intelligence, Customer Service, Language Technology, Customer Marketing, Artificial Intelligence, Language
Project
, according to a front-line source in artificial intelligence, is in the midst of initiatives related to real-time insights. The organization is currently evaluating Google BigQuery. These efforts are focused on inventory control and ordering.
Analytics & Insights, Artificial Intelligence
Project
, according to a front-line source in artificial intelligence, is planning to begin initiatives related to data labeling within three months. Parabilis Medicines is expected to increase contingent workforce to support these efforts.
Data Management, Contingent Workforce, Artificial Intelligence
Project
Data Management, Data Science, Artificial Intelligence
Parabilis Medicines News & Media
Parabilis holder reports Series F convertible stake | PBLS Insider Trading - Stock Titan
Soleus-affiliated entities report Series F Preferred Stock in Parabilis Medicines, convertible into 527,070 common shares at $9.48 per share, establishing 10%+ ownership.Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy?
Parabilis Medicines, a Cambridge, Massachusetts, biotech innovator in oncology, reported a notable insider buy amid ongoing development of cancer therapies.StockWatch: Parabilis Medicines Makes Wall Street History with $770.5M IPO
In what’s shaping up to be a historic year for biotech initial public offerings, Parabilis Medicines made its mark on Wall Street this past week by pricing the largest-ever IPO by a drug developer. This upsized offering raised an eye-popping $770.5 million in gross proceeds.Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
CAMBRIDGE, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease, today announced the closing of its upsized initial public offering of an aggregate 38,525,000 shares of its common stock, including the full exercise by the underwriters of their overallotment op
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Parabilis Medicines
Sign Up For FreeTo access detailed company insights
Parabilis Medicines is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines that unlock high-impact protein targets long-considered undruggable. Leveraging over a decade of proprietary data, laboratory innovations, and AI- and physics-based algorithms, the company has developed a new class of stabilized, cell-pen... Read More
